tradingkey.logo
๎™

Oncology Institute Inc

TOI
3.342USD
-0.048-1.41%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย ๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
326.11M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

์ž์„ธํ•œ ๋‚ด์šฉ์€ Oncology Institute Inc ํšŒ์‚ฌ

The Oncology Institute, Inc. is a value-based oncology company. The Company manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The Company's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The Company also provides management services to over 14 clinic locations owned by independent oncology practices. The Company and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.

Oncology Institute Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ TOI
ํšŒ์‚ฌ ์ด๋ฆ„Oncology Institute Inc
์ƒ์žฅ์ผMar 13, 2020
CEOVirnich (Daniel)
์ง์› ์ˆ˜825
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒMar 13
์ฃผ์†Œ18000 Studebaker Rd
๋„์‹œCERRITOS
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€United States of America
์šฐํŽธ ๋ฒˆํ˜ธ90703
์ „ํ™”15627353226
์›น์‚ฌ์ดํŠธhttps://theoncologyinstitute.com/
์ข…๋ชฉ ์ฝ”๋“œ TOI
์ƒ์žฅ์ผMar 13, 2020
CEOVirnich (Daniel)

Oncology Institute Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
+1.07%
Mr. Brad Hively
Mr. Brad Hively
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
712.03K
+51.10%
Ms. Anne Mcgeorge
Ms. Anne Mcgeorge
Independent Chairman of the Board
Independent Chairman of the Board
291.37K
+58.92%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
289.09K
+45.97%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.37K
+0.08%
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
196.63K
+1.86%
Ms. Kristin England
Ms. Kristin England
Chief Administrative Officer
Chief Administrative Officer
98.04K
--
Mr. Mark L. Pacala
Mr. Mark L. Pacala
Independent Director
Independent Director
--
--
Ms. Karen M. Johnson
Ms. Karen M. Johnson
Independent Director
Independent Director
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Dr. Daniel Virnich, M.D.
Dr. Daniel Virnich, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.20M
+1.07%
Mr. Brad Hively
Mr. Brad Hively
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
712.03K
+51.10%
Ms. Anne Mcgeorge
Ms. Anne Mcgeorge
Independent Chairman of the Board
Independent Chairman of the Board
291.37K
+58.92%
Dr. Mohit Kaushal
Dr. Mohit Kaushal
Independent Director
Independent Director
289.09K
+45.97%
Mr. Robert Ross Carter
Mr. Robert Ross Carter
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
235.37K
+0.08%
Dr. Yale Podnos
Dr. Yale Podnos
Chief Medical Officer
Chief Medical Officer
196.63K
+1.86%

์ˆ˜์ต ๋ถ„์„

ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Oct 6
ํ†ตํ™”: USD๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
Dispensary revenue
62.57M
52.23%
FFS revenue
37.05M
30.92%
Capitated revenue
18.84M
15.73%
Clinical research trials and other revenue
1.34M
1.12%
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
์‚ฌ์—…๋ณ„USD
์ด๋ฆ„
์ˆ˜์ต
๋น„์œจ
Dispensary revenue
62.57M
52.23%
FFS revenue
37.05M
30.92%
Capitated revenue
18.84M
15.73%
Clinical research trials and other revenue
1.34M
1.12%

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Fri, Dec 5
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Fri, Dec 5
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
M33 Growth LLC
5.53%
The Vanguard Group, Inc.
4.62%
OncologyCare Partners LLC
4.18%
Deerfield Management Company, L.P.
3.42%
BlackRock Institutional Trust Company, N.A.
3.17%
๊ธฐํƒ€
79.09%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
M33 Growth LLC
5.53%
The Vanguard Group, Inc.
4.62%
OncologyCare Partners LLC
4.18%
Deerfield Management Company, L.P.
3.42%
BlackRock Institutional Trust Company, N.A.
3.17%
๊ธฐํƒ€
79.09%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Investment Advisor
12.34%
Hedge Fund
11.00%
Investment Advisor/Hedge Fund
10.03%
Venture Capital
5.53%
Individual Investor
4.89%
Corporation
4.18%
Research Firm
0.92%
Private Equity
0.26%
Bank and Trust
0.17%
๊ธฐํƒ€
50.68%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Oct 1
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Oct 1
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q3
145
39.72M
42.48%
-7.79M
2025Q2
119
39.72M
44.51%
-19.63M
2025Q1
137
46.36M
52.04%
-13.47M
2024Q4
138
45.05M
59.62%
-19.81M
2024Q3
139
50.89M
67.39%
-11.59M
2024Q2
143
57.80M
76.77%
-3.05M
2024Q1
146
56.10M
75.87%
-3.90M
2023Q4
143
57.48M
77.79%
-4.30M
2023Q3
176
58.70M
79.97%
-14.73M
2023Q2
180
58.28M
81.90%
-25.39M
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
M33 Growth LLC
8.52M
9.12%
-5.15M
-37.65%
Sep 04, 2025
The Vanguard Group, Inc.
4.28M
4.58%
+2.53M
+144.52%
Jun 30, 2025
OncologyCare Partners LLC
4.11M
4.4%
--
--
Mar 26, 2025
Deerfield Management Company, L.P.
3.36M
3.59%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.00M
3.2%
+2.74M
+1088.12%
Jun 30, 2025
CenterBook Partners LP
715.90K
0.77%
+715.90K
--
Jun 30, 2025
Balyasny Asset Management LP
2.52M
2.69%
+371.00K
+17.28%
Jun 30, 2025
Wexford Capital LP
1.12M
1.2%
+1.12M
--
Jun 30, 2025
Geode Capital Management, L.L.C.
1.28M
1.37%
+893.70K
+231.68%
Jun 30, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
์ด๋ฆ„
๋น„์œจ
Vanguard US Momentum Factor ETF
0.11%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
ProShares UltraPro Russell2000
0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Vanguard US Momentum Factor ETF
๋น„์œจ0.11%
iShares Micro-Cap ETF
๋น„์œจ0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
๋น„์œจ0.03%
Global X Russell 2000 ETF
๋น„์œจ0.01%
ProShares Hedge Replication ETF
๋น„์œจ0.01%
iShares Russell 2000 ETF
๋น„์œจ0.01%
Proshares Ultra Russell 2000
๋น„์œจ0.01%
ProShares UltraPro Russell2000
๋น„์œจ0.01%
Invesco Russell 2000 Dynamic Multifactor ETF
๋น„์œจ0.01%
iShares Russell 2000 Growth ETF
๋น„์œจ0.01%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ
๋‚ ์งœ
์œ ํ˜•
๋น„์œจ
๋ฐ์ดํ„ฐ ์—†์Œ

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Oncology Institute Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋ˆ„๊ตฌ์ธ๊ฐ€์š”?

๎™Œ
Oncology Institute Inc์˜ ์ƒ์œ„ 5๋Œ€ ์ฃผ์ฃผ๋Š” ๋‹ค์Œ๊ณผ ๊ฐ™์Šต๋‹ˆ๋‹ค:
M33 Growth LLC๋Š” 8.52M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 9.12%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
The Vanguard Group, Inc.๋Š” 4.28M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 4.58%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
OncologyCare Partners LLC๋Š” 4.11M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 4.40%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
Deerfield Management Company, L.P.๋Š” 3.36M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 3.59%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.
BlackRock Institutional Trust Company, N.A.๋Š” 3.00M์ฃผ์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ์ „์ฒด ์ฃผ์‹์˜ 3.20%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค.

Oncology Institute Inc์˜ ์ƒ์œ„ 3๋Œ€ ์ฃผ์ฃผ ์œ ํ˜•์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Oncology Institute Inc์˜ ์ฃผ์š” ์ฃผ์ฃผ ์œ ํ˜• ์ƒ์œ„ 3๊ฐ€์ง€๋Š”
M33 Growth LLC
The Vanguard Group, Inc.
OncologyCare Partners LLC์ž…๋‹ˆ๋‹ค.

Oncology Institute Inc(TOI)์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ๋ช‡ ๊ฐœ์ž…๋‹ˆ๊นŒ?

๎™Œ
2025Q3 ๊ธฐ์ค€์œผ๋กœ, Oncology Institute Inc์˜ ์ฃผ์‹์„ ๋ณด์œ ํ•œ ๊ธฐ๊ด€์€ ์ด 145๊ณณ์ด๋ฉฐ, ์ด๋“ค์ด ๋ณด์œ ํ•œ ์ฃผ์‹์˜ ์ด ๊ฐ€์น˜๋Š” ์•ฝ 39.72M๋กœ ์ „์ฒด ๋ฐœํ–‰ ์ฃผ์‹์˜ 42.48%๋ฅผ ์ฐจ์ง€ํ•ฉ๋‹ˆ๋‹ค. ์ด๋Š” 2025Q2 ๋Œ€๋น„ -2.03% ์ฆ๊ฐ€ํ•œ ์ˆ˜์น˜์ž…๋‹ˆ๋‹ค.

Oncology Institute Inc์˜ ์ตœ๋Œ€ ์ˆ˜์ต์›์€ ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
FY2025Q2 ๊ธฐ์ค€, Oncology Institute Inc์˜ Dispensary revenue ๋ถ€๋ฌธ์ด ๊ฐ€์žฅ ๋†’์€ ๋งค์ถœ์„ ๊ธฐ๋กํ–ˆ์œผ๋ฉฐ, ๊ธˆ์•ก์€ 62.57M๋กœ ์ „์ฒด ๋งค์ถœ์˜ 52.23%๋ฅผ ์ฐจ์ง€ํ–ˆ์Šต๋‹ˆ๋‹ค.
KeyAI
๎™